---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-25-000086"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:18:54.942102+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Keros net loss narrows to $7.3M in Q3; cash runway into H1 2028

## Summary
- Net loss of $7.3M in Q3 2025 versus $53.0M in Q3 2024, driven by Takeda license revenue.
- R&D expenses fell to $19.5M from $49.2M after elritercept transition to Takeda.
- Cash and equivalents $693.5M; board authorized $375M return to stockholders.
- Takeda plans to initiate Phase 3 trial of elritercept in first-line myelodysplastic syndromes.
- Keros expects to fund operations into H1 2028 after capital return.

## SEC filing metadata
- accession: 0001664710-25-000086
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000086/0001664710-25-000086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000086/kros-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-25-000086
- JSON: https://secwatch.observer/filing/0001664710-25-000086.json
- Plain text: https://secwatch.observer/filing/0001664710-25-000086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.